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Abstract
Background: Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may
have synergistic activity in treating advanced gastric cancer. We performed a phase I study of
docetaxel and 5-FU to determine the maximum tolerated dose (MTD), the recommended dose for
phase II studies, and the safety of this combination.
Methods: Eligible patients had recurrent and/or metastatic advanced gastric cancer with normal
cardiac, renal and hepatic function. Traditional phase I methodology was employed in assessing
dose-limiting toxicity (DLT) and MTD. On day 1 every 3 weeks, docetaxel 75 mg/m2 (fixed dose)
was infused over 1-h, followed immediately by 5-FU as a 5-day continuous infusion.
Results: Dose escalation schema was as follows: dose level (DL) 1 (5-FU 250 mg/m2/day), 2 (500),
3 (750), and 4 (1000). Three patients were enrolled on DL1, without DLT. On DL2, 1 DLT (grade
3 stomatitis) was developed in first 3 patients, and this cohort was expanded to 6 patients. Three
patients had been enrolled on DL3. Because two out of 3 patients had DLTs, the MTD was reached
at DL3.
Conclusion: The recommended phase II dose of this combination is 75 mg/m2 docetaxel on day
1 immediately followed by a 5-day continuous infusion of 5-FU 500 mg/m2/day.
Background
Gastric cancer remains the most common cause of cancer-
related death in Korea [1]. For patients with unresectable,
locally advanced, or metastatic disease, chemotherapy can
provide significant palliation of symptoms [2,3]. When
used as single agents, 5-fluorouracil (5-FU), doxorubicin,
cisplatin, and mitomycin C are considered active in gastric
cancer, producing response rates in up to 20% of patients
[4]. Of these, 5-FU is an central cytostatic antimetabolite
with a broad range of antitumor activity in breast, gas-
trointestinal, head and neck, and ovarian cancers. When
given as a prolonged continuous infusion, stomatitis and
diarrhea are the principal toxicities, whereas myelosup-
pression is more commonly observed with intravenous
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bolus injections [5,6]. Because 5-FU has demonstrated
synergistic interaction with many antineoplastic agents, it
is currently most often administered in the setting of com-
bination chemotherapy regimens. However, most trials
with different combinations of these drugs provided sim-
ilar survivals ranging from 6 to 10 months [7,8]. No regi-
men has been universally recognized as standard.
Among the new agents, docetaxel is a novel semisynthetic
taxane with significant antitumor activity and manageable
toxicity consisting primarily of myelosuppression [9].
Results of docetaxel-containing regimen in the treatment
of gastric cancer are encouraging. Phase I and II clinical tri-
als have confirmed that docetaxel is effective in patients
with advanced gastric cancer when used as monotherapy,
yielding response rates of 20% [10,11]. Docetaxel and 5-
FU are highly synergistic [12], and clinical evidence sug-
gests lack of cross-resistance.
When this study was initiated, most previous studies used
docetaxel 60–85 mg/m2 on day 1, followed by a 5-day
continuous infusion of 5-FU 500–1000 mg/m2/day, every
3 weeks [12-15]. However, we had experienced severe tox-
icities such as febrile neutropenia and grade 3 or 4 stoma-
titis in treating patients with advanced gastric cancer as a
practice with docetaxel 75 mg/m2 and 5-FU 1000 mg/m2/
day for 5 days. Therefore, we performed a phase I study of
docetaxel and 5-FU to determine the maximum tolerated
dose (MTD) and the safety of this combination.
Methods
Patients
This was a phase I dose-escalating study conducted
between Mar 2002 and Aug 2002. The study was con-
ducted according to the principles stated in the latest ver-
sion of the Declaration of Helsinki. This study protocol
was reviewed and approved by the Gil Medical Center
institutional review board, and signed informed consent
was obtained from all patients prior to their enrollment.
Patients enrolled into this study had to be at least 18 years
of age and have a histologically confirmed diagnosis of
metastatic or recurrent gastric adenocarcinoma that was
previously treated with, though not necessarily resistant
to, cytotoxic chemotherapy. The patients were required to
have a Eastern Cooperative Oncology Group (ECOG) per-
formance status ≤ 2, normal blood counts, normal renal
and hepatic functions, no history of anaphylaxis and no
peripheral neuropathy of any origin. Patients had to have
received at least one chemotherapy regimen, either as
adjuvant treatment or for metastatic disease. Patients
could have received prior 5-FU, provided it was adminis-
tered in intravenous bolus or in oral form, but not with
paclitaxel or docetaxel. Patients had to have fully recov-
ered from the toxic effects of previous chemotherapy
except for alopecia.
Treatment plan
The treatment consisted of docetaxel 75 mg/m2 on day 1
in a 1-h infusion followed by 5-FU in continuous infusion
from day 1 to day 5, according to the escalating dose lev-
els. The starting dose of 5-FU was 250 mg/m2/day for 5
days. In the absence of DLT, dose escalation in additional
cohorts continued at a dose increase of 250 mg/m2/dose.
Traditional phase I methodology was employed in assess-
ing dose-limiting toxicity (DLT) and MTD. Patients were
to be treated at the same dose level in groups of three. If
no DLT, defined as febrile neutropenia and/or grade 3/4
toxicity of any other kind apart from alopecia, occurred,
the next 3 patients were treated at the next higher dose
level. If one DLT occurred, 3 additional patients had to be
treated at the same dose level. If 2 or more DLTs occurred
at a given dose level, the MTD would be considered to be
reached and the dose escalation had to be stopped. The
dose just below would be considered to be the recom-
mended dose for further evaluation in phase II trials.
Only the first cycle of treatment was evaluated to deter-
mine DLT. However, to adequately determine to safety of
this combination, the recruitment of further patients at
the recommended dose level was planned in a subsequent
phase II study [16]. All patients received a standard sup-
portive regimen consisting of dexamethasone and 5-HT3
inhibitors. The use of hematological growth factors was
not allowed during the first cycle of treatment, but was
permitted thereafter among patients who had one episode
of febrile neutropenia or infection according to the guide-
line provided by American Society of Clinical Oncology
[17].
Table 1: Patient characteristics
Number of patients N = 16
Age
Median 59
Range 36–73
Male:female 14:2
ECOG performance status
0 6 37%
1 8 50%
2 2 13%
Disease status
Primary metastatic 12 75%
Locally-advanced 4 25%
Prior chemotherapy
Uracil-tegafur 4 25%
5-FU bolus + folinic acid 1 6%
5-FU + cisplatin 4 25%
Epirubicin + cisplatin + capecitabine 5 31%
Epirubicin + doxorubicin + cisplatin 2 13%BMC Cancer 2005, 5:87 http://www.biomedcentral.com/1471-2407/5/87
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Patient evaluation
Toxicity was graded according to National Cancer Insti-
tute Common Toxicity Criteria for adverse events (NCI-
CTC) [18]. Dose modifications were planned for toxicity.
The primary objective of the study was to define the MTD
of the regimen under investigation. Evaluation at baseline
and during the study included a medical history, data on
toxicity and physical examination every courses.
Results
Patient characteristics
Sixteen patients received a total of 45 cycles of treatment
(median 3, range 1–6). Patient characteristics are listed in
Table 1. All patients previously received one cytotoxic
chemotherapy regimen, with 88% having received prior
fluoropyrimidines. Previous chemotherapy was com-
monly administered as adjuvant treatment (4 patients,
25%) or for metastatic disease (12 patients; 75%). Twelve
patients (75%) had no measurable lesions to evaluate
treatment efficacy.
Toxicity
All patients were evaluable for toxicity. Of three patients
enrolled on dose level 1 (5-FU 250 mg/m2/day for 5
days), none experienced DLT. On dose level 2 (5-FU 500
mg/m2/day for 5 days), a 63-year-old male with perito-
neal dissemination developed grade 3 stomatitis and
fatigue. Three additional patients were enrolled at this
dose level did not experience DLT. Dose escalation thus
proceeded to dose level 3 (5-FU 750 mg/m2/day for 5
days). One of the 3 initial patients at this level, a 57-year-
old male with peritoneal dissemination developed grade
3 stomatitis and another patient, a 60-year-old male with
liver metastasis had febrile neutropenia. Because two out
of 3 patients had DLTs, the MTD was reached at dose level
3. Dose level 2 was therefore the recommended regimen
with docetaxel 75 mg/m2 on day 1 and 5-FU 750 mg/m2/
day in a 5-day continuous infusion.
Toxicity analysis is based on 16 patients and 45 cycles of
treatment. Table 2 summarizes DLTs per patients and per
cycles. No treatment-related death was observed.
Discussion
This phase I trial determined the recommended phase II
dose of 5-FU to be 500 mg/m2/day as a 5-day continuous
infusion when combined with 75 mg/m2 docetaxel every
3 weeks. DLTs included stomatitis, neutropenia, diarrhea,
and asthenia. Toxicity in our study did not differ signifi-
cantly from that seen in other phase I studies that evalu-
ated docetaxel combined with 5-FU continuous infusion.
A phase I trial showed that docetaxel at 85 mg/m2 with 5-
FU given in continuous infusion over 5 days at 750 mg/
m2/day was tolerable without any major mucosal toxicity
or any substantial increase in docetaxel-induced myelo-
toxicity [12]. Ando et al. [13] determined the MTDs of
docetaxel and 5-FU on this schedule to be 50 mg/m2 and
500 mg/m2/day, respectively, and neutropenia to be the
primary DLT, with diarrhea also dose limiting. Using a
similar schedule, Van den Neste et al. [14] reported the
MTDs of docetaxel and 5-FU to be 85 mg/m2 and 750 mg/
m2/day, with diarrhea, stomatitis and neutropenia as
DLTs.
Because of the relatively high incidence of hematologic
toxicity induced by docetaxel, it was felt that only a mod-
erately myelotoxic agent could be added as a combina-
tion. 5-FU given in continuous infusion could be an
interesting option since it is known to induce very little
myelotoxicity, if any.
With the addition of 5-FU, the main changes in the non-
hematologic toxicity were observed in the occurrence of
stomatitis and diarrhea, and in the appearance of hand-
foot syndrome. All three toxicities are known to be associ-
ated with 5-FU. Hawkins et al. [15] compared docetaxel
with the addition of irinotecan or 5-FU in a randomized
phase II study. Both docetaxel/irinotecan and docetaxel/
5-FU were well-tolerated with acceptable toxicity profiles.
Three-drug combination of docetaxel, 5-FU and cisplatin
for patients with gastric cancer was also investigated by
some authors. Roth et al. [19] administered combination
chemotherapy with docetaxel 85 mg/m2, cisplatin 75 mg/
m2, and 5-FU 300 mg/m2/day on days 1–14, resulting in
a 51% objective response. The major toxicity was neutro-
Table 2: Dose-limiting toxicities (DLTs) according to dose level.
Dose level (5-FU/day) Pts/cycles After first cycle After all courses (pts/cycles)
Neutropenia FN1 stomatitis diarrhea asthenia
Level 1 (250 mg) 3/4 None 1/1 1/1
Level 2 (500 mg) 10/35 Stomatitis (1) 4/5 6/11 1/1 4/7
Level 3 (750 mg) 3/4 Stomatitis (1)
FN (1)
2/2 1/1 2/2 1/1 1/1
1 FN denotes febrile neutropenia.BMC Cancer 2005, 5:87 http://www.biomedcentral.com/1471-2407/5/87
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penia which reached grade 3 or 4 in 79% of 52 patients.
Ajani et al. [20] evaluated a combination of docetaxel, cis-
platin, and 5-FU (DCF) for chemotherapy-naïve patients
with advanced gastric cancer. They achieved a response
rate of 39% and median survival of 10.2 months, and tox-
icity was manageable. It is apparent that the more com-
plex a chemotherapy regimen, the more toxic and difficult
for patients to tolerate. Although cisplatin is often used in
combination with other agents, it is well known that cis-
platin is associated with significant toxicity and usually
requires high level of clinical monitoring and supportive
care including intensive intravenous hydration. Thuss-
Patience et al. [21] recently reported that docetaxel/5-FU
had similar efficacy to epirubicin/cisplatin/5-FU (ECF)
and even to DCF.
Since nearly 80% of the patients did not have measurable
disease, an efficacy assessment could not be performed in
this patient population. Our randomized phase II trial
with docetaxel/5-FU versus paclitaxel/5-FU is currently
ongoing [16].
Conclusion
In conclusion, the recommended dose of this combina-
tion is 75 mg/m2 docetaxel on day 1 immediately fol-
lowed by a 5-day continuous infusion of 5-FU 500 mg/
m2/day. Further evaluation of efficacy and safety is cur-
rently underway in a randomized phase II trial of 5-FU
combined with docetaxel versus paclitaxel.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
SHP collected the data, performed the statistical analysis
and drafted the manuscript. SB, EKC, JHL, WKL and MC
followed the patients. DBS designed the study and helped
with the manuscript. All authors read and approved the
final manuscript.
References
1. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean
central cancer registry program 2000.  Cancer Res Treat 2002,
34:77-83.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised com-
parison of fluorouracil, epidoxorubicin and methotrexate
(FEMTX) plus supportive care with supportive care alone in
patients with non-resectable gastric cancer.  Br J Cancer 1995,
71:587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U,
Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Rand-
omized comparison between chemotherapy plus best sup-
portive care with best supportive care in advanced gastric
cancer.  Ann Oncol 1997, 8:163-168.
4. Murad AM: Chemotherapy for Advanced Gastric Cancer:
Focus on New Agents and Combinations.  Cancer Control 1999,
6:361-368.
5. Seifert P, Baker LH, Reed ML, Vaitkevicius VK: Comparison of con-
tinuously infused 5-fluorouracil with bolus injection in treat-
ment of patients with colorectal adenocarcinoma.  Cancer
1975, 36:123-128.
6. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective
randomized comparison of continuous infusion fluorouracil
with a conventional bolus schedule in metastatic colorectal
carcinoma: a Mid-Atlantic Oncology Program Study.  J Clin
Oncol 1989, 7:425-432.
7. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA,
Krook JE, Mailliard JA, Tschetter LK: Controlled evaluation of
three drug combination regimens versus fluorouracil alone
for the therapy of advanced gastric cancer. North Central
Cancer Treatment Group.  J Clin Oncol 1994, 12:412-416.
8. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi
N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Rand-
omized phase III trial of fluorouracil alone versus fluorour-
acil plus cisplatin versus uracil and tegafur plus mitomycin in
patients with unresectable, advanced gastric cancer: The
Japan Clinical Oncology Group Study (JCOG9205).  J Clin
Oncol 2003, 21:54-59.
9. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semi-
synthetic analogue of taxol.  J Natl Cancer Inst 1991, 83:288-291.
10. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders
J, Franklin H, LeBail N, Verweij J: Docetaxel (Taxotere) in
advanced gastric cancer: results of a phase II clinical trial.
EORTC Early Clinical Trials Group.  Br J Cancer 1994,
70:380-383.
11. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA,
Benson AB: Phase II trial of docetaxel (Taxotere) in patients
with adenocarcinoma of the upper gastrointestinal tract
previously untreated with cytotoxic chemotherapy: the
Eastern Cooperative Oncology Group (ECOG) results of
protocol E1293.  Med Oncol 1996, 13:87-93.
12. Burris HA 3rd: Docetaxel in combination with fluorouracil for
advanced solid tumors.  Oncology (Williston Park) 1997, 11:50-52.
13. Ando M, Watanabe T, Sasaki Y, Ying DF, Omuro Y, Katsumata N,
Narabayashi M, Tokue Y, Fujii H, Igarashi T, Wakita H, Ohtsu T, Itoh
K, Adachi I, Taguchi T: A phase I trial of docetaxel and 5-day
continuous infusion of 5-fluorouracil in patients with
advanced or recurrent breast cancer.  Br J Cancer 1998,
77:1937-1943.
14. Van Den Neste E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z,
Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H,
Cazenave I, Lefresne-Soulas F, Piccart M: A phase I and pharma-
cokinetic study of docetaxel administered in combination
with continuous intravenous infusion of 5-fluorouracil in
patients with advanced solid tumors.  Clin Cancer Res 2000,
6:64-71.
15. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon JL, Lopez-
Vivanco G, Jacques C, Stenger P, Zuber E, Misset JL: Randomized
phase II trial of docetaxel plus irinotecan versus docetaxel
plus 5-fluorouracil (5FU) in patients with untreated
advanced gastric adenocarcinoma (AGAC).  Proc Am Soc Clin
Oncol 2003, 22:257 (abstr 1032).
16. Park SH, Kim MJ, Chung M, Lee WK, Bang SM, Cho EK, Shin DB, Lee
JH: Interim analysis from a prospective randomized trial of
taxanes plus 5-FU in advanced gastric cancer.  Proc Am Soc Clin
Oncol 2004, 22:361 (abstr 4191).
17. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo
PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ,
Wozniak AJ, Somerfield MR: 2000 update of recommendations
for the use of hematopoietic colony-stimulating factors: evi-
dence-based, clinical practice guidelines. American Society
of Clinical Oncology Growth Factors Expert Panel.  J Clin Oncol
2000, 18:3558-3585.
18. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehen-
sive criteria for assessing therapy-induced toxicity.  Cancer
Invest 1990, 8:147-159.
19. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann
R, Borner MM, Goldhirsch A, de Braud F: 5-Fluorouracil as pro-
tracted continuous intravenous infusion can be added to full-
dose docetaxel (Taxotere)-cisplatin in advanced gastric car-
cinoma: a phase I-II trial.  Ann Oncol 2004, 15:759-764.
20. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis
A, Boni C, Zuber E, Blattmann A: Docetaxel (D), cisplatin, 5-
fluorouracil compare to cisplatin (C) and 5-fluorouracil (F)
for chemotherapy-naive patients with metastatic or locallyPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:87 http://www.biomedcentral.com/1471-2407/5/87
Page 5 of 5
(page number not for citation purposes)
recurrent, unresectable gastric carcinoma (MGC): Interim
results of a randomized phase III trial (V325).  Proc Am Soc Clin
Oncol 2003, 22:249 (abstr 999).
21. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser
D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P: Docetaxel
and Continuous-Infusion Fluorouracil Versus Epirubicin, Cis-
platin, and Fluorouracil for Advanced Gastric Adenocarci-
noma: A Randomized Phase II Study.  J Clin Oncol 2005,
23:494-501.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/87/prepub